Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

906
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
906
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

295
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
295
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

380
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
380
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

236
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
236
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

242
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
242
Coronary Circulation01:21

Coronary Circulation

6.9K
The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
6.9K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Independent and Dose-Dependent Contributions of Clonal Hematopoiesis and Mosaic Loss of Y to Incident Heart Failure.

European journal of heart failure·2026
Same author

Geriatric nutritional risk index associated to long-term prognosis and length of hospitalization in the contemporary transcatheter aortic valve replacement era.

Journal of geriatric cardiology : JGC·2026
Same author

FEV1 is a major prognostic factor in diverse heart failure populations: findings from the Global Heart Failure registry.

ESC heart failure·2026
Same author

Endothelial ZBTB16: a molecular shield against cardiac aging.

European heart journal·2026
Same author

Atherosclerosis licenses for an exceeding immune response in COVID-19 disease by interferon priming in circulating myeloid cells.

Cardiovascular research·2025
Same author

The European BestAgeing Study on microRNA candidates reveals distinct signatures with diagnostic and prognostic potential in cardiovascular disease.

BMC medicine·2025

関連する実験動画

Updated: Jan 24, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.7K

急性冠動脈症候群後の死亡率に対するアリロキュマブの効果

Philippe Gabriel Steg1,2, Michael Szarek3, Deepak L Bhatt4

  • 1Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Université de Paris, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Paris, France (P.G.S.).

Circulation
|May 24, 2019
PubMed
まとめ

アリロキュマブは急性冠動脈症候群の患者で,特に治療期間が長くなり,LDLコレステロール値が低下すると,全因死亡率が著しく低下しました. このPCSK9阻害剤は,高リスクの心血管疾患患者の死亡率に潜在的利点をもたらします.

キーワード:
PCSK9タンパク質急性冠動脈症候群アリロキュマブコレステロール死亡率

さらに関連する動画

Portable Thermographic Screening for Detection of Acute Wallenberg's Syndrome
05:12

Portable Thermographic Screening for Detection of Acute Wallenberg's Syndrome

Published on: September 19, 2019

7.0K
Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome
06:06

Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome

Published on: October 26, 2018

10.3K

関連する実験動画

Last Updated: Jan 24, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.7K
Portable Thermographic Screening for Detection of Acute Wallenberg's Syndrome
05:12

Portable Thermographic Screening for Detection of Acute Wallenberg's Syndrome

Published on: September 19, 2019

7.0K
Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome
06:06

Oleic Acid-Injection in Pigs As a Model for Acute Respiratory Distress Syndrome

Published on: October 26, 2018

10.3K

科学分野:

  • 心臓病科
  • 薬理学について
  • 臨床試験

背景:

  • 前回のプロプロテイン変換酵素9型 (PCSK9) 阻害剤試験では,心血管疾患の減少が認められたが,死亡率は認められなかった.
  • ODYSSEY OUTCOMES試験では,急性冠動脈症候群 (ACS) の後の死亡に対するアリロキュマブの効果を調査した.

研究 の 目的:

  • ACS後の患者における全因死亡率およびその成分に対するアリロキュマブの影響を評価する.
  • 達成された低密度脂質タンパク質コレステロール (LDL-C) 値と死亡率の利益との関係を評価する.

主な方法:

  • 最近のACSとスタチンの治療でLDL- Cが上昇した18,924人の患者を対象とした二重盲検ランダム化試験です.
  • アリロキュマブの投与量は,25- 50 mg/ dLのLDL- Cを達成するために調整され,結果はプラセボと比較された.
  • ログランクテストと関節半パラメトリックモデルは,死亡と心血管疾患を分析するために使用されました.

主要な成果:

  • アリロキュマブは,すべての原因による死亡率 (HR 0. 85,P=0. 03) を,平均2. 8年の追跡期間で減少させた.
  • 3年以上の追跡期間で,前述の分析で死亡率に有意な改善が見られた (HR 0. 78,P=0. 01).
  • 死亡率の減少は,初期LDL- C≥100 mg/ dLと,LDL- Cレベルが約30 mg/ dLに達した患者で顕著であった.

結論:

  • アリロキュマブは,スタチンの集中治療に追加された場合,ACS後の死亡率を低下させる可能性があります.
  • 治療期間 ≥3年,LDL-Cのベースライン ≥100 mg/ dL,および低レベルのLDL-Cの達成は,死亡率の利点を高めます.